A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.  We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.

This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel

Full paper in Lancet Oncology here 

More than 500 salvage radical prostatectomies!!! Yep it would be fair enough to describe Dr Paul Cathcart as being "experienced" in the most challenging scenario  we face as prostate cancer surgeons. Surgery for cancer recurrence in the prostate following radiotherapy or various forms of ablative therapy is never easy, and can all too often lead to issues with healing and quality of life recovery due to the impact of prior failed treatments, so we are always keen to see how we can improve outcomes. 
Paul dropped into the GU Cast studio when back in Melbourne this week, a little over ten years on from his Fellowship training here. He is a Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, where his main area of expertise is indeed salvage robotic radical prostatectomy. Paul shares his perspectives and tips and tricks for performing this procedure to try and give patients the best possible outcome, and also explains why he prefers the da Vinci Surgical System over the new robot kids on the block.
This is a Themed Podcast supported by our Silver Partners, Device Technologies, distributors of the da Vinci Surgical System.

Even better on our YouTube channel

There are patient advocates and there are patient advocates, and then there is Howard Wolinsky! We chat with the inimitable Howard, medical journalist and very long-time active surveillance patient, about his varied interests in low-risk prostate cancer and prostate cancer diagnostics. He runs a great substack called The Active Surveillor with a regular newsletter which we devour every week! l His  current interests are in the abolition of transrectal prostate biopsy and the campaign to re-name grade group 1/Gleason 6 cancer as a non-cancer. We chat about all this and more, including that unforgettable appearance he made at the ASCO GU Plenary session!

Also available on our YouTube channel

Subscribe to the Active Surveillor here 

Fascinating GU Cast today focussing on the role of MRI scanning for patients on active surveillance (AS) for prostate cancer. We are joined by two of the world's leading experts on prostate MRI to discuss two recent systematic reviews on this topic.  Professor Anwar Padhani, Radiologist at Mt Vernon Cancer Centre and the Institute of Cancer Research  in London, and Professor Caroline Moore, Urologist at University College London, give some fascinating insights and tackle some controversial questions.
Patients and clinicians would love to avoid further biopsies as part of active surveillance monitoring. However, repeat biopsy remains a strong recommendation in all AS guidelines. Anwar reviews the two recent systematic reviews (links below), plus his recent European Urology editorial, and Caroline reveals what they currently offer patients at UCL (spoiler alert - they don't do routine biopsies on AS)!
Anwar also introduces the very valuable work of the International Cancer Imaging Society, and we talk about the fantastic collection of talks he posts on his very popular YouTube channel. Links all below.
Usual hosts Declan Murphy and Renu Eapen. Enjoy!

Links:
Eur Urol systematic review
Eur Urol Oncol systematic review
Anwar's Editorial in Eur Urol
Anwar's YouTube channel
International Cancer Imaging Society
Anwar's twitter
Caroline's twitter

Cracking episode today, following hot on the heels of the systematic review recently published in European Urology focussing on #manels in urology. We cross the globe to hear from first author Dr Jeremy Teoh in Hong Kong, senior author Dr Maria Ribal in Barcelona, and co-authors Dr Stacy Loeb in New York, and our own Declan Murphy in Melbourne. This paper has got a big reaction on social media and we review some of the best and the worst of twitter in our chat today. Enjoy! 

Links:
Eur Urol paper on #manels
Jeremy Teoh twitter

Big week for prostate cancer ( especially for PSMA enthusiasts like us!), with the phase III VISION trial heading the plenary session at the ASCO Annual Meeting. VISION is the long-awaited pivotal randomised trial of Lu-PSMA vs standard of care for men with progressive mCRPC following chemo +/- AR pathway inhibitors. Lots of stuff to dive into, even as we await the NEJM paper. We scrutinise the control arm and dive deep into teh issue of imaging and patient selection.
Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined by some of our experienced Lu-PSMA specialists at Peter Mac, Professor Michael Hofman and Associate Professor Arun Azad.

Links;
Dr Mike Morris Twitter
UroToday report from Dr Chris Wallis

Today Declan and Renu recall one of the highlights of ASCO GU 2020 (the last real physical meeting!!),  when Dr David Penson delivered his keynote address on financial toxicity in GU Oncology. David's team also followed up with a fantastic systematic review on this completely under-discussed topic in European Urology Oncology recently (link below). David is Professor and Chair of Urology at Vanderbilt University Medical Centre in Nashville, and has had a distinguished career investigating quality of life in prostate cancer patients, particularly as PI of the Prostate Cancer Outcomes Study. No holds barred today as we discuss everything from bankruptcy-free survival to the ludicrous lack of support for de-escalation studies in GU Oncology. Plus of course, we indulge his love of golf for just a bit.

Links:
David Penson Twitter (Urogeek) - highly recommended!
Recent systematic review on financial toxicity in Eur Urol Oncol
Urotoday coverage of David's ASCO GU 2020 talk
Stacey Dusetzina twitter
Royal Portrush GC (in memory of Jimmy Penson, a proper golfer!)

GU Cast is back! Declan and Renu took a break over the Melbourne Summer and are fully recharged with a great schedule of podcasts coming up for 2021.
We kick off today with the fourth in our series of webinar collaborations with the Prostate Cancer Foundation and the ProsTIC team at Peter MacCallum Cancer Centre. Today's webinar had 589 live attendees from more than 40 countries, tuning in to hear the latest in PSMA theranostics for advanced prostate cancer. 
ON GU Cast today we cross-post the audio from today's webinar focussing on the TheraP trial, recently published in the Lancet. TheraP is the first randomised trial of 177Lutetium PSMA theranostics, and is one of the most exciting areas of research in prostate cancer today.
We are joined by both the first and senior authors, Professors Michael Hofman and Professor Ian Davis, as well as key members of the team who put this together, including funders, industry partners, and a panel of expert key opinion leaders including panellist Professor Louise Emmett.
Special thanks to Dr Howard Soule and Dr Andrea Miyahira from the PCF, as well as Professor Michael Hofman and Annette Van Der Heyden from ProsTIC for putting this together.

Links:
The PCF
ProsTIC
TheraP page at ANZUP
Full webinar on YouTube

Today we are getting together on New Year's Eve 2020 to look back on the year that was. Very forgettable for many reasons(!), but also some great moments on GU Cast that we want to share with you on our Year in Review podcast. 
Since our launch episode in March 2020, we have posted 45 episodes and have had many thousands of downloads every month. Our audience  is truly global with listeners from 75 countries in 2020,  the majority of whom (59%) are from outside Australia. 
We play back some very memorable moments from the past nine months, and chat about some of our personal highlights of GU Cast 2020. Plus we reveal our most listened to podcast this year. 
We are very grateful to the very many (>60!) national and international guests who joined the podcast this year, and to our regular studio guests who really added value to GU Cast this year. We look forward to bringing you even more great content in 2021!

Wishing you all a Happy New Year! 

Declan and Renu and all at GU Cast

We know that many of our listeners are in the depths of a tough COVID Winter in the Northern Hemisphere, so we thought we might bring you some summer cheer from Australia where the sun is shining and COVID is less of an issue! 
We have joined with our friends at PROSPECT, a prostate cancer educational initiative which has been running in Australia for eight years. to bring you a 3-part podcast summer series focussing on our favourite hot topics in prostate cancer. Today we focus on two areas with a big crossover - so-called "non-metastatic (M0)" castration-resistant prostate cancer (CRPC), and PSMA PET/CT. The past year has been a bog one for PSMA PET/CT and we are delighted to welcome two of the world's leading experts in PSMA PET/CT, Professor Michael Hofman from Peter MacCallum Cancer Centre in Melbourne, and Dr Jeremie Calais from the University of California, Los Angeles, to discuss the recent FDA approval and the data that has informed this. Plus we are joined by Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre and Chair of the PROSPECT Steering Committee, to discuss the overall survival data for androgen receptor pathway inhibitors in M0 CRPC, and to consider what wider availability of PSMA PET/CT means for this disease area. Your usual hosts are Professor Declan Murphy and Dr Renu Eapen from Peter Mac. 

PROSPECT and our GU Cast Summer Series are supported by an educational grant from Janssen Oncology in Australia. 

Big day today with the approval of Ga68-PSMA PET/CT by the US Food and Drugs Administration (FDA). The FDA have approved a combined academic application from the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA), and means that those two centres now have FDA approval to use PSMA PET/CT for staging newly-diagnosed prostate cancer, as well as those with suspected recurrence following previous treatment.
Today we chat with the UCSF team behind the application, led by Dr Thomas Hope, Nuclear Medicine Physician and Radiologist, and his urology colleagues Dr Peter Carroll and Dr Matt Cooperberg. Fantastic discussion about what this means for access to PSMA PET/CT across the whole country; what it means for trial design; what other agents are on the horizon; and a steal peak from Dr Carroll about other research areas in PSMA he is exploring at UCSF.
Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined once again by Professor Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre.

Links
FDA news release on PSMA PET/CT
UCSF Urology
UCSF Nuclear Medicine
UCLA Urology
UCLA Nuclear Medicine

"Men urged to harden up on prostate health" - so goes the title of Libbi Gorr's interview with our own Declan Murphy when she chatted with him this week on her ABC Radio show, "This Weekend Life". A no-holds barred chat on all things prostate to coincide with Movember. Featuring calls from patients, and a discussion about how often men should ejaculate!

Links
Libbi's show on ABC Radio

The European Association of Nuclear Medicine (EANM) Annual Meeting is the world's leading nuclear medicine congress, and took place (virtually) last week. From being a very minor part of nuclear medicine just a few years ago, GU Oncology is now one of the most exciting areas in nuclear medicine, and this year's EANM Meeting featured a huge amount of original research in prostate cancer and other GU malignancies.
Today we are joined by EANM Congress Chair, Dr Stefano Fanti from Bologna, Italy, and Dr Irene Burger, Head of Nuclear Medicine in Baden, to review the top papers from this year's meeting, and a peak into future directions for nuc med in GU oncology.
Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined once again  by Professor Michael Hofman, Director of the Prostate Theranostics and Image Centre of Excellence at Peter Mac.

Useful links:
EANM
Michael Hofman plenary talk at #EANM20
Our "Going Nuclear" paper in BJUI 2019
Plus short accompany video 

Part 2 of our Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this episode we chat with Elena Castro, Nick James, Anthony Joshua, Bertrand Tombal, Silke Gillessen, Aurelius Tomlin, Yüksel Ürün, Gill Morgan, and a gang of nuclear medicine phyicians including Michael Hofman, Louise Emmett, Tom Hope, Stefano Fanti, and Ken Herrmann.

GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast.

Even better on our YouTube channel

It's that time of year again, and we are celebrating all things Mo with Paul Villanti, Executive Director at Movember. From its humble origins here in Melbourne 13 years ago, the Movember campaign has raised more than AUD$1.1bn over the past 13 years, funding more than 1250 projects around the world aimed at improving men's health. Quiet amazing, and a lot of fun. Prostate and testicular cancer have been particularly high priority areas for support, and we were keen to hear more of this and also to hear about the usual fun initiatives which Movember build into their campaigns.
Paul popped in to our studio to tell us about some of the highlights of this year's Movember, and to talk of some of the key initiatives which Movember support.
And what is a ChocoMo??? You'll have to tune in to find out!

Links:
Movember
ChocMo (courtesy of Dr Christian Wagner, Gronau, Germany) 

Today we focus on the NAVIGATE study,  a randomised trial of an online decision aid for men and their partners recently diagnosed with localised prostate cancer. Active surveillance is the preferred option for many men with low-risk prostate cancer, and may also be recommended for some men with favourable intermediate-risk prostate cancer, but many patients find the idea of surveillance to be stressful, and find the choice of management options to be bewildering. So today we chat with some of the team behind the NAVIGATE study which is designed to address some of these issues. NAVIGATE is running in Australia, sponsored by Swinburne University with the trial team based at Peter MacCallum Cancer Centre.
Joining us in studio are Natalie Richards who is a research nurse and NAVIGATE Project Manager, Alan White, patient representative on the project, and via Zoom is Dr Matt Roberts, a urologist in Brisbane who is actively enrolling patients. We also hear from a patient who is actively participating in the study and provides a terrific perspective having been on surveillance initially, and then went on to have surgery when his cancer changed while on surveillance. Your co-hosts are Declan Murphy and Renu Eapen from Peter Mac.
NAVIGATE is 80% recruited and is expected to finish recruitment in 2021. See below for details of how to find out more. Patients may be referred by their clinician or may self-refer directly to the NAVIGATE team if their cancer is suitable for surveillance. The Principal Investigator is Professor Penelope Schofield and the trial is funded by an NHMRC grant.

More info
NAVIGATE trial website
NAVIGATE info on Peter Mac website
Prostate Cancer Foundation of Australia

Regular GU Cast guest, Dr Ben Tran, joins us today to review some highlights from the recent virtual #ESMO20 Annual Meeting. Ben made headlines himself at this year's meeting as he presented his phase 1 study of AMG160 was selected for the prostate cancer plenary session (you got to tune in to hear him explain what a half-life extended bi-specific T cell engager is! Peter Mac Phase I and GU Fellow, Dr Ciara Conduit, also joins us to discuss this and other highlights including IPAT, PROfound, and the Checkmate 9ER study for mRCC. Usual hosts Declan Murphy and Renu Eapen. 

Exciting day today with the publication of the first edition of a brand new urology journal! And not one of those horrible predatory journals that we all get harassed by.
The Societe Internationale d'Urologie (SIU) is one of the leading organisations in urology and has a long history of partnering with other major journals to output their scientific content. It has now decided to publish its own journal, the SIU Journal, and today we were delighted to speak with their Editor-in-Chief, Professor Peter Black, from Vancouver and the University of British Columbia. Peter is very well known in the world of urology as a huge leader in GU Oncology, so it is very exciting to see him turn his talents to leading this journal. We are very confident himself and his very global editorial team will produce a fantastic journal. 

Links:
SIU Journal

Twitter
SIU Journal
SIU
Professor Peter Black

Today we join forces again with our good friends at the Prostate Cancer Foundation (PCF) to bring you the podcast version of the PCF Global Knowledge Exchange, this time focussing on Next Generation PSMA. Today's event is brought to you by PCF in conjunction with the Prostate Imaging and Theranostics Centre of Excellence (ProsTIC) at Peter MacCallum Cancer Centre in Melbourne. Your hosts are Dr Howard Soule and Dr Andrea Miyahira from the PCF, and Professor Michael Hofman and Professor Declan Murphy from ProsTIC.
PSMA imaging and theranostics are among the most exciting areas of research in prostate cancer, and today's event involves top leaders in the field who are tasked with looking beyond what we are using today. This PCF Global Knowledge Exchange is a full webinar which included more than 500 delegates from around the world, and we have posted the link to the YouTube version below. In the meantime, we hope that you might enjoy this podcast.

Speakers and topics include:
- Prof. Klaus Kopka: PSMA evolution
- Prof. Neil Bander: combination alpha-Ab / small molecule
- Dr Cristina Müller: Terbium PSMA
- Prof. Mike Sathekge: theranostics in low-mid income countries
- A/Prof Ana Kiess: auger-emitters to target micro-metastases
- Prof. John Babich: albumin-binding to increase uptake

Full webinar on Youtube
Click here

Links:
PCF
ProsTIC

Twitter:
PCF Science
ProsTIC
Peter Mac GU Onc

A big week for prostate cancer in the Lancet! No less than three much-anticipated randomised trials to investigate the role of adjuvant vs salvage radiotherapy in prostate cancer, were published in the Lancet and Lancet Oncology this week, plus a pre-planned meta-analysis of all three. RAVES, RADICALS-RT, and GETUG-AFU 17, each examined the issue of post-operative radiotherapy in men at risk of biochemical recurrence, and randomised those men to receive radiotherapy prior to PSA recurrence (adjuvant), or at the first sign of PSA recurrence (early salvage). There were some differences in patient population and trial design, but the overall message is that early salvage radiotherapy offers the same oncological benefit as adjuvant radiotherapy, with significantly less toxicity. An accompanying pre-planned meta-analayis (ARTISTIC), and Editorial reinforce the message.
GU Cast hosts Professor Declan Murphy and Dr Renu Eapen were delighted to speak today with RAVES lead author Professor Andrew Kneebone of Royal North Shore Hospital/University of Sydney, and co-author Professor Mark Frydenberg of Monash University, about the results of this trial and what it means for patients at risk of biochemical recurrence following radical prostatectomy. Truly practice-defining studies!

Links:
RAVES paper
RADICALS
GETUG-17
ARTISTIC meta-analysis
Lancet Editorial

TROG
ANZUP

Today we focus on trainee-led collaborative research, focussing on three of the best examples out there. We chat with the leaders of the British Urology Researchers in Surgical Training (BURST), the European Society of Residents in Urology (ESRU), and the Australian Young Urology Researchers Organisation (YURO). These groups have a number of missions, including networking and mentorship for trainees, but they also have a particular interest in collaborative research. We chat with Veeru Kasi and Meg Kulkarni from BURST, Diego Carrion Monsalve from ESRU, and Ellen O'Connor from YURO, about the beginnings of their respective organisations, how they function, their successes to date, and some of the challenges they face. We hear of some amazing examples of trainee-led research involving many thousands of patients, 50+ centres in multiple countries, with impressive publications to date. We also hear how organisations such as BAUS, EAU, and USANZ, and journals including BJUI, European Urology Today, and Minerva Urologica e Nefrologica have supported trainee-led research, but how more can be done to foster these initiatives.

Hosted by Declan Murphy and Renu Eapen from Peter MacCallum Cancer Centre.

Website Links:
BURST
ESRU
YURO

Twitter
BURST
ESRU
YURO
Veeru Kasi
Meg Kulkarni
Diego Carrion Monsalve
Ellen O'Connor

Others:
Join the BURST RESECT Study
BURST paper on communication in COVID era
Legends of Urology podcast

Continuing our season of chats with newly-minted Editors-in-Chief of top urology journals, today we chat with Dr Mike Leveridge of the Department of Urology, Queen's University, Ontario. Mike has just taken the reins as Editor-in-Chief of the Canadian Association of Urology (CUA) Journal, one of our favourite national journals, and has just published his opening editorial. CUA J is open access with no article processing fees - the rest of teh world should follow this example!!
One of our all time favourite friends in North America, and a great choice to lead this really useful journal. Usual hosts Declan Murphy and Renu Eapen are joined by colleague Nathan Lawrentschuk, who did Fellowship training with Mike in Toronto.

CUA Journal 
Mike's fantastic Twitter feed
Mike's debut editorial 

Uro-Twitterati legend Dr Ben Davies joins us today to trawl through his Twitter feed and share his wisdom on everything from tomatoes to leadership positions in Urology. Ben is Professor of Urology at the University of Pittsburgh, Chief of Urology at Shadyside/Hillman Cancer Centre and Director of the Uro-Oncology Fellowship Program. No holds barred chat with one of our favourite friends in Urology! With your usual hosts, Declan Murphy and Renu Eapen. 

Ben's Twitter feed https://twitter.com/daviesbj 

Professor Freddie Hamdy, Professor of Urology at the University of Oxford, has recently taken up the reigns as Editor-in-Chief of the British Journal of Urology International (BJUI) and has just published the first edition with his new editorial team. The BJUI has been around for more than 90 years and is one of the top journals in the world of urology. Its impact factor rose to an all-time high under the leadership of Prof Hamdy's predecessor. Professor Prokar Dasgupta, who also led a huge change to embrace digital and social media, and therefore Prof Hamdy takes over at an exciting time. 
Usual hosts Professor Declan Murphy (a past Associate Editor of BJUI) and Dr Renu Eapen (who recently joined the Editorial Board), are joined by Associate Professor Nathan Lawrentschuk who continues as Associate Editor in charge of the BJUI supplement. 

Pelvic lymph node dissection down-graded. Systematic prostate biopsies no longer recommended. More clarity around PSMA PET/CT for staging. Surgery no longer recommended for cN1 prostate cancer. Yep the recent updates to the EAU Prostate Cancer Guidelines had a lot of important changes for the global urology community to digest. So we invited EAU Prostate Cancer Guideline Vice-Chair Derya Tilki, and Guideline Board Member Gianluca Giannarini, along with Elio Mazzone to join us for a deep dive into these major changes.  All you need to know!

Even better on our YouTube channel 

Tim O'Brien, Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, joins GU Cast to chat about his recent appointment as President of The British Association of Urological Surgeons. Tim has taken the reigns of BAUS during these most extraordinary of times, and is determined to make the most of the opportunities! Nothing like a pandemic to help make some changes. Tim joins usual hosts Declan Murphy and Renu Eapen for a most entertaining and insightful chat. 

Today we are joined by USANZ President, Dr Stephen Mark, to discuss the big challenges faced by trainees during COVID. We include soundbites from many trainees and aspiring trainees who sent in voice memos to highlight the stresses and concerns they have - some  amazing comments! Stephen responds to these concerns and gives us a glimpse into USANZ plans for the future. 
Regular hosts Declan Murphy and Renu Eapen are joined by Associate Professor Nathan Lawrentschuk. 

Today GU Cast again joins up with our good friends at Urotoday.com to cross post this episode. Our own Dr Renu Eapen is interviewed by Dr Ashish Kamat (an old friend of GU Cast), as part of the Urotoday Bladder Cancer Centre of Excellence, to discuss urinary diversion in female patients following radical cystectomy. 
You can find the original Urotoday post, including some supporting slides, on the following link https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/1844-urinary-diversion-in-women-following-radical-cystectomy-renu-eapen.html 

With the COVID pandemic situation continuing to worsen in Melbourne, further restrictions have been put in place for elective surgery. Pre-op COVID swabs are already mandatory, and now only the most urgent surgeries can go ahead. We are joined by the Directors of three of Melbourne's busiest urology cancer centres to see what this means for patients. Professor Damien Bolton from the Austin, Associate Professor Nathan Lawrentschuk from the Royal Melbourne Hospital (and Peter Mac), and co-host Professor Declan Murphy from Peter Mac. Dr Renu Eapen is co-host as ever. 

Today we chat with Dr Paul Cathcart, Urologist at Guy's & St Thomas' NHS Foundation Trust in London, who has a specialist interest in salvage radical prostatectomy. Paul is one of the world's most experienced salvage prostatectomists and joins us to chat about patient selection and surgical technique to optimise outcomes, especially for patients who have undergone focal therapy. Post-HIFU/brachy/cryo/Nano knife - he does them all! And has published lots of data in this area.
Paul also chats about the UK National Prostate Cancer Audit as he leads the Quality group in this huge project. Co-hosts Declan Murphy and Renu Eapen from Peter MacCallum Cancer Centre in Melbourne.

Today Melbourne is back in lockdown (boo), so to cheer ourselves up, we bring you a fantastic GU Cast with two great guests! Dr Jim Porter from Seattle has hit the headlines twice recently; first with a superb randomised trial of a point of surgical technique during robotic prostatectomy recently published in the BJUI; and second, the global headlines that he made when he mentored Dr Archie Fernando perform a complex robotic surgery in London, while in his pyjamas in Seattle! We chat with the founder and CEO of Proximie, whose technology enabled this, Dr Nadine Haram, an extraordinary surgical entrepreneur. Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined by Peter Mac colleague, Associate Professor Daniel Moon. 

Today we look forward to #EAU20, the Annual Meeting of the European Association of Urology (EAU). Like all other scientific meetings at present, #EAU20 is not taking place in its usual format as a huge physical meeting (due to be in Amsterdam), but is instead a fully virtual meeting taking place from 17-19th July 2020. 
Today we chat with the Chair of the EAU Scientific Congress Office, Professor Peter Albers, about the challenges in switching over to a virtual meeting, and about the fantastic format they have created so delegates can still enjoy the usual very high quality EAU meeting experience. 
We also chat with Prof Joan Palou, Chair of the EAU European School of Urology about the UroWebinars which they are putting on in lieu of their usual program of educational courses. It all sounds fantastic!!! 
Full details here https://eaucongress.uroweb.org 

Dr Archie Fernando is a Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, specialising in testicular cancer and retroperitoneal fibrosis. BAUS posted a terrific video which she did recently to share her perspectives on telehealth, based on an interesting case she had recently had, and she shares seven great tips on telehealth for clinicians. Join Declan and Renu for a terrific podcast with Archie. 
Here is a link to her original video https://youtu.be/P3c3ZvVI-OY 

GU Cast today features two excellent online initiatives to facilitate online education. 
We are joined in studio by Associate Professor Jeremy Grummet, Urologist, to talk about https://www.mripro.io which provides an outstanding platform to learn how to interpret MRI prostate. A very well annotated set of 300 cases are presented in a very user-friendly platform with CME approval. Also a great set of multidisciplinary webinars. 
And Dr Lindsay Hampson joins us from California to discuss the fantastic online urology education program, #UrologyCOViD, which she and her colleagues have developed during COVID times. Originally aimed at urology residents in the USA, but with many trainees from all over the world joining in. 

We are joined today by the fantastic Dr Neeraj Agarwal of the Huntsman Cancer Institute in Utah to discuss some contentious areas in mCRPC, especially around DNA repair defects, immunotherapy and other targeted therapies. Also joined again in studio by our colleague Associate Professor Arun Azad, and regular hosts Declan Murphy and Renu Eapen.

The first of two Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this epsiode we chat with Silke Gillessen, Derya Tilki, Jochen Walz, Neha Vapiwala, Dingwei Ye, and the lucky trainees who won a GU Cast Travel Award to attend this year's APCCC. 

GU Cast Conference Highlights are supported by our friends at Bayer China, Gold Partners of GU Cast.

Even better on our YouTube channel 

GU Cast chats to Dr Petros Grivas, GU Medical Oncologist at the University of Washington in Seattle, about the JAVELIN 100 trial which featured in the plenary session at ASCO20 recently. Petros is senior author on this practice-changing study of "switch maintenance" in metastatic bladder cancer, and he joins us today to explain some of the finer details of the study. With audio cameos from Tom Powles, Betsy Plimack, and Vinay Prasad (yikes!). 
Declan and Renu were also delighted to have Associate Professor Andrew Weickhardt join them in studio today. Andrew is a GU Medical Oncologist at the Olivia-Newton John Cancer Centre and Austin Hospital in Melbourne, where he leads the GU Oncology trials team. 

Another most enjoyable webinar from our friends at the Prostate Cancer Foundation, this time focussing on the TheraP trial recently presented at #ASCO20, a randomised trial of Lu-PSMA vs cabazitaxel in progressive mCRPC. Professor Michael Hofman presents the data and is joined by an esteemed global panel including Professor Ian Davis, Professor Cora Sternberg and Professor Wolfgang Weber. Co-hosted by Professor Declan Murphy and Dr Howard Soule. More than 500 registrants from over 40 countries joined in, many of whom contributed to a very lively discussion. Enjoy!

Dr Ashish Kamat, Professor of Urologic Onology at MD Anderson Cancer Centre joins us for a chat about the BADAS trial which he is leading. Fascinating trial to see if BCG vaccination might protect health care workers. And of course we talk bladder cancer as Ashish is a huge key opinion leader with many leadership roles in bladder cancer research and advocacy. 
usual hosts Declan Murphy and Renu Eapen are joined by Associate Professor Nathan Lawrentschuk from Peter Mac. Nathan is also Director of Urology at the Royal Melbourne Hospital and leads Bladder Cancer Australia. 

Dr Sumanta Pal from City of Hope, CA, joins us to discuss renal cancer highlights at virtual #ASCO20. Monty heads the renal cancer program at City of Hope and is a huge KOL in renal cancer. Also great fun on Twitter @montypal of course. 
Enjoy this fireside chat with Monty, Dr Ben Tran, medical oncologist at Peter Mac, and regular hosts Declan Murphy and Renu Eapen. 
PS our podcast art today features Monty and Eric Jonasch when they popped in to see us at Peter Mac in February 2018. Nice pose gents!

Dr Elizabeth Plimack, Chief of GU Medical Oncology at Fox Chase Cancer Centre, Philadelphia, joins us to discuss bladder cancer highlights at ASCO 20. For the first time, urothelial cancer featured in an ASCO Plenary with Dr Tom Powles presenting the primary endpoint of JAVELIN100, a practice-changing study of switch-maintenance in metastatic urothelial cancer. Betsy did a fantastic discussion in the plenary and joins us today to discuss this and others. Regular hosts Declan Murphy and Renu Eapen are joined by Dr Ben Tran, GU Trials Lead at Peter MacCallum Cancer Centre.

The first in our series of post-#ASCO20 podcasts. Today we chat with Dr Oliver Sartor of Tulane Cancer Centre about his favourite prostate cancer moments from virtual #ASCO20. PSMA imaging and therapy, neo-adjuvant intensive ADT, M0 CRPC etc etc - all get a mention in a whirlwind run through the main prostate cancer sessions. 
Regular hosts Declan Murphy and Renu Eapen are joined by Peter Mac colleagues, Associate Professor Arun Azad and Professor Michael Hofman. 

We are joined today by Alan and Fiona White to discuss their perspectives as a couple who have been on this journey, and who spend a lot of time supporting other couples. Alan had an open radical prostatectomy in 2011, and himself and Fiona have developed https://www.theprostatezone.com to help others on the journey. 
Regular hosts Declan Murphy and Renu Eapen are also joined by prostate cancer Nurse Consultant, Emma Birch. 

We are re-posting this podcast which ABC Radio National posted in Feb 2020, featuring our own Declan Murphy and Peter Mac colleague, Professor Rob Ramsay, top scientist and prostate cancer patient. Some wonderful perspectives and very nicely put together by Natasha Mitchell from the Science Friction podcast at the ABC. Here is their blurb - 

You're a top cancer scientist. You think you know a lot about the disease. And then you get it. Suddenly you're "A Cancer Patient", and one of your colleagues is wielding the (robotic) scalpel in your surgery. 

Tables are turned, but once a scientist always a scientist, even on the operating table. 

A story about science, knowledge, and vulnerability. Don't miss this frank and fearless conversation about an experience many men don’t talk openly about.

Guests:

Professor Robert Ramsay
Cancer scientist
Co-Head Gastrointestinal Cancer Program
Peter MacCallum Cancer Centre, Victoria, Australia 

Professor Declan Murphy
Urologist and Director of Genitourinary Oncology
Peter MacCallum Cancer Centre and University of Melbourne
Declan on Twitter @declangmurphy

Presenter/producer: Natasha Mitchell
Sound engineer: Krissy Miltiadou

Duration: 28min 49secBroadcast: Sun 2 Feb 2020, 5:05pm

Today we are joined by Professor Nick James, Principal Investigator of the STAMPEDE study; an amazing ongoing series of practice-changing randomised trials for men with advanced prostate cancer. Nick discusses recent highlights of STAMPEDE, imminent developments in STAMPEDE, the impact of PSMA PET/CT, as well as some challenges in the COVID era. He also discusses his recent move from Birmingham to the Institute of Cancer Research/Royal Marsden, and his son's recent Zoom wedding in South America! Regular hosts Declan Murphy and Renu Eapen are joined in studio by Associate Professor Arun Azad, medical oncologist at Peter MacCallum Cancer Centre. 

Today we are joined by Nurse Consultants, Emma Birch and Marc Diocera, and also by patient advocate Alan White, to discuss how they work together to prepare patients and their loved ones who are coming up to robotic prostatectomy. They describe the evolution of their "Robocare" program over teh past ten years, and look ahead to how COVID19 is creating opportunities to make it even more accessible. Hosted by Declan Murphy and Renu Eapen. 

Didn't get to ASCO this year?? Us neither!! But not to worry, we checked in with Dr Marty Schoen who did, and brings us all the key highlights! Marty is a GU Medical Oncologist at the St Louis Veterans Affairs Medical Centre and the University of St Louis, Missouri. He runs through a smattering of stuff that caught his eye at ASCO this year. Thanks Marty!

Also on our YouTube channel

Today we hook up with our good friends at Urotoday.com. Dr Alicia Morgans interviews Professor Declan Murphy for the Urotoday.com website, and we are cross-posting as a GU Cast podcast, introduced by Dr Renu Eapen. Alicia interviews Declan about the COVID situation in Australia as part of the Urotoday.com global overview. 

Dr Matt Cooperberg from UCSF joins us on GU Cast to give us his Top 5 "Good Things to Come Out of COVID". The usual mixture of banter and bonhomie with Declan Murphy and Renu Eapen from Peter MacCallum Cancer Centre. Enjoy!!

Today we are joined by three giants in the world of stereotactic-assisted body radiotherapy (SBRT), to discuss the use of SBRT in various stages of prostate cancer. Associate Professor Shankar Siva from Peter MacCallum Cancer Centre joins us in the studio, along with Dr Alison Tree from the Royal Marsden in London, and Dr Piet Ost from Ghent. Your usual hosts are Professor Declan Murphy and Dr Renu Eapen.